BriaCell Therapeutics Corp. and its majority‑owned subsidiary BriaPro Therapeutics Corp. completed an asset purchase transaction on March 31 2026 that transferred BriaCell’s exclusive license to develop and commercialize soluble CD80 (sCD80) to BriaPro. The deal also gives BriaPro a 78 % ownership stake in BriaCell through the issuance of 23,972,589 common shares, valued at approximately C$1.18 million, and provides BriaCell with a $3 million credit facility to fund research and development.
Under the terms of the transaction, BriaPro will pay BriaCell a 2 % royalty on sales revenue from any sCD80 product that reaches commercialization. The deal received approval from 99.81 % of BriaPro’s disinterested shareholders and was structured to comply with Canadian securities regulations, including the Multilateral Instrument 61‑101 for special transactions.
BriaCell’s shift to focus on its own immunotherapy candidates is complemented by the sCD80 platform, which BriaPro will advance through pre‑clinical and early‑phase studies. BriaPro’s pipeline includes binding agents and proteins designed to enhance the body’s cancer‑fighting cells, and the sCD80 technology offers a potential combination therapy with BriaCell’s existing candidates such as Bria‑IMT and Bria‑OTS+. The transaction provides BriaCell with immediate capital and a controlling interest in the entity that will drive the sCD80 development, positioning the company for future partnership or acquisition opportunities.
Financially, BriaPro reported a net loss of $472,231 for the six months ended January 31 2026, driven by research and development spending. The company’s negative working capital and a material uncertainty about its ability to continue as a going concern underscore the importance of the $3 million credit facility, which will support BriaPro’s ongoing R&D activities and help mitigate short‑term liquidity risks.
BriaCell’s CEO, Bill Williams, said, “Our mission has been to develop safe and effective treatments for cancer patients who do not respond to existing treatments, and a transformational anti‑cancer agent such as sCD80 may provide us with such an additional opportunity. Based on the promising data in animal studies, we plan to explore the potential use of sCD80 technology as a therapeutic agent in combination with our other immunotherapies or on its own. We look forward to accelerating the development of this novel anti‑cancer agent to bring hope to patients who need it the most.”
The transaction delivers BriaCell with a significant capital infusion and a strategic foothold in a promising biologic platform. While BriaPro’s financial position remains fragile, the credit facility and BriaCell’s majority ownership provide a safety net that could accelerate sCD80’s progression toward clinical trials and, ultimately, commercialization. The deal also signals BriaCell’s intent to diversify its oncology portfolio and leverage external expertise to advance a high‑potential asset.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.